E. AlejandroSweet-CorderoMD
Pediatric Hematology & Oncology • Palo Alto, CAProfessor of Pediatrics, University of California San Francisco
Overview of Dr. Sweet-Cordero
I am a physician-scientist and cancer biologist. I am board-certified in pediatric oncology and I direct the UCSF Molecular Oncology Initiative.
Office
725 Welch Rd
Palo Alto, CA 94304
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1999 - 2002
University of California (San Francisco)Residency, Pediatrics, 1995 - 1998- University of California San Francisco School of MedicineClass of 1995
Certifications & Licensure
CA State Medical License 1997 - 2025
MA State Medical License 1999 - 2006- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Member, American Society for Clinical Investigation ASCI, 2011
Publications & Presentations
PubMed
- The CLCF1-CNTFR axis drives an immunosuppressive tumor microenvironment and blockade enhances the effects of established cancer therapies.Eric Sweet-Cordero, Kieren Marini, Emma Champion, Alex Lee, Isabelle Young
Research Square. 2024-03-22 - 2 citationsDetection of a GLIS3 fusion in an infant with AML refractory to chemotherapy.Stephen M Smith, Alex Lee, Schuyler Tong, Stanley Leung, Henry Hongo
Cold Spring Harbor Molecular Case Studies. 2022-08-04 - 9 citationsAPOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.Divya Natesan, Li Zhang, Henry J Martell, Tanya Jindal, Patrick Devine
Frontiers in Oncology. 2022-01-01
Press Mentions
- AACR Research Highlights from UCSFApril 6th, 2022
- Upcoming AACR Virtual Meeting on Sarcomas Spotlights Early-Career ResearchersJune 24th, 2021
Protein Decoy Stymies Lung Cancer Growth in Stanford-UCSF StudyNovember 7th, 2019
Grant Support
- Mechanisms Of Chemotherapy Response And Tumor Re-Initiation In Lung CancerNational Cancer Institute2011–2012
- Comparative Functional Genomics For Lung Cancer Gene DiscoveryNational Cancer Institute2008–2011
- Identification Of Novel KRAS Effector Pathways In Lung CancerNational Cancer Institute2009–2010
- Tumor Progression In A Mouse Model Of Lung CancerNational Cancer Institute2005–2007
- Tumor Progression In A Mouse Model Of Lung CancerNational Cancer Institute2003–2004
External Links
- lab websitehttps://sweetcorderolab.ucsf.edu/
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS California PPO
BCBS Georgia Blue Choice HMO
BCBS Georgia Blue Open Access POS
BCBS Georgia BlueChoice Option POS
BCBS Illinois BlueChoice Select
BCBS Illinois PPO
Capital Blue Cross PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPOFirst Health PPO
Great West PPO
Health Net California Large Group PPO
Highmark BCBS ClassicBlue
Highmark BCBS PPOBlue
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PHCS PPO - Kaiser
Multiplan PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
